BOSTON--(BUSINESS WIRE)--Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced ...
Immune exclusion, or the lack of immune cells in the vicinity of cancer cells, predicts poor patient outcomes in multiple cancers, including triple-negative breast cancer (TNBC). Now, researchers have ...
Redx Pharma plc has described henyl- and pyridopyrazole derivatives as discoidin domain-containing receptor DDR1 and/or DDR2 inhibitors. They are reported to be useful for the treatment of fibrosis, ...
September 2nd, 2019, 4 PM, London, Insilico Medicine, a global leader in artificial intelligence for drug discovery, today announced the publication of a paper titled, "Deep learning enables rapid ...
Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in oncology. One of the key reasons lies in the disease's unique fibrotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback